4 NEWS DAILY NEWS CPHI 2025 FRANKFURT DAY 1 | 28th October 2025 VERDOT, a French leader in downstream bioprocessing technologies, is pleased to announce a new strategic agency partnership with GMI, a trusted provider of laboratory solutions headquartered in Ramsey, Minnesota, USA. This agreement marks a significant step in VERDOT’s expansion into the United States, bringing its cutting-edge single-use systems to a broader range of biopharmaceutical manufacturers. GMI has served the life sciences industry since 1995, delivering high-quality laboratory equipment and services to academic institutions, research organizations, and industrial clients across the U.S. The company is recognized for its commitment to customer support, extensive service expertise, and dedication to helping laboratories achieve cost-effective performance. Through this partnership, GMI will act as an agent for VERDOT’s singleuse FlexiPro™ and conventional MiniPro™ systems, enabling U.S. clients to benefit from VERDOT’s unique expertise in GMP purification and downstream processing from pilot through commercial production scales. Together, the two companies will support biopharmaceutical and biotechnology firms with solutions designed to optimize workflows, accelerate development timelines, and increase access to advanced therapies. Charles Ruban, President and CEO of VERDOT, stated, “We are thrilled to announce our partnership with GMI. Their expertise in purification equipment, combined with their commitment to quality and customer service in the U.S., makes them the perfect partner for VERDOT. Through this collaboration, we will be able to propose our unique FlexiPro™ Chrom and TFF product lines, renowned for their flexibility and performance, to a broader audience of biotech, CDMO, and biopharma customers. We look forward to achieving great success together.” Justin Volling, President and CEO of GMI commented, “We are beyond excited to partner with VERDOT, a company that shares GMI’s commitment to exceptional customer experience, sustainability, and uncompromising quality. We’re confident that our team’s expertise, experience and base of loyal customers will help amplify VERDOT’s offering of tailored purification solutions in North America. This partnership is an immensely impactful addition as we continue to deliver unparalleled value to our customers.” This partnership will leverage VERDOT’s decades of expertise in downstream purification with GMI’s established U.S. network to provide customers with high-performance, cost-effective purification solutions that drive innovation in biopharmaceutical manufacturing. VERDOT and GMI announce new agency partnership to strengthen bioprocessing and advance biopharmaceutical manufacturing in the United States FDA approves Boehringer drug to treat idiopathic pulmonary fibrosis The U.S. FDA announced approval of Boehringer Ingelheim’s Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF) on October 7th. According to the agency press release, this is the first new therapy approved in over 10 years for IPF. Per the release, approval of nerandomilast was based on two Phase III randomized, double-blind, placebo-controlled trials involving adults with IPF. The primary endpoint was the absolute change from baseline in Forced Vital Capacity (FVC), or the maximum amount of air a person can forcefully exhale after taking the deepest possible breath. The study found that individuals taking nerandomilast had a significantly smaller FVC decline compared to placebo-treated patients. IPF is a rare disease that affects the tissue surrounding the alveoli in the lungs. Over time, it can cause permanent lung scarring, making it more difficult to breathe. The disease has no known cure and limited treatment options. “Today’s approval furthers FDA’s longstanding commitment to support treatment options for patients and advances in health care for the American public,” said the agency in the release.
RkJQdWJsaXNoZXIy MjY2OTA4MA==